Covered recipient · General Payments record
JOEL M BELTRAN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
This page merges CMS profile IDs 11436476, 337883 — associated profiles published by CMS for the same covered recipient. See the colophon below.
General Payments · PY2018–2023
$10,276.23
- Reported across 729 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $387.51 | 14 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $128.98 | 3 |
| UCB, Inc. | $78.40 | 3 |
| Lilly USA, LLC | $27.33 | 1 |
| Amneal Pharmaceuticals LLC | $25.96 | 1 |
| Amgen Inc. | $24.88 | 1 |
| Genentech USA, Inc. | $22.66 | 1 |
| Biogen, Inc. | $22.20 | 1 |
| ACADIA Pharmaceuticals Inc | $20.54 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.20 | 1 |
| Medtronic, Inc. | $16.36 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $20.54 | 01/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1053118045 | CMS |
| Amgen Inc. | $24.88 | 01/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019967617 | CMS |
| Amneal Pharmaceuticals LLC | $25.96 | 02/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1053477713 | CMS |
| Biogen, Inc. | $22.20 | 03/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1012270175 | CMS |
| EMD Serono, Inc. | $86.94 | 02/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032415543 | CMS |
| EMD Serono, Inc. | $33.86 | 02/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032455261 | CMS |
| EMD Serono, Inc. | $8.18 | 03/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032455335 | CMS |
| Genentech USA, Inc. | $22.66 | 01/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040401545 | CMS |
| Lilly USA, LLC | $27.33 | 02/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1031508331 | CMS |
| Medtronic, Inc. | $16.36 | 02/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019776007 | CMS |
| Novartis Pharmaceuticals Corporation | $20.20 | 03/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991686085 | CMS |
| UCB, Inc. | $31.87 | 01/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1021411999 | CMS |
| UCB, Inc. | $30.70 | 03/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1021411993 | CMS |
| UCB, Inc. | $15.83 | 03/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1021411985 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
- Merged CMS profile IDs
- 11436476, 337883
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.